EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Metformin does not slow cyst growth in the PCK rat model of polycystic kidney disease

Ozgur A Oto, Daniel J Atwood, Anjana Chaudhary, Zhibin He, Amy S Li, Michael F Wempe, Charles L Edelstein iD

Physiological Reports · 2023

DOI: 10.14814/phy2.15776 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Physiological Reports, 2023. Verfasst von Ozgur A Oto und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Polycystic Kidney Diseases, Cysts, Metformin, Renal Insufficiency. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, BLRD VA, Office of Extramural Research, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metformin (MET) has the potential to activate p‐AMPK and block mTORC1‐induced proliferation of tubular cells in PKD kidneys. The aim of this study was to determine the effects of MET on cyst growth, kidney function, AMPK and mTOR signaling, and lactate levels in male PCK rats, a Pkhd1 gene mutation model of human autosomal recessive polycystic kidney disease (ARPKD). MET 300 mg/kg/day IP from days 28 to 84 of age resulted in a mean serum metformin level that was 10 times the upper limit of therapeutic, no effect on cyst indices, nephrotoxicity, and increased serum lactate. MET 150 mg/kg resulted in a therapeutic serum metformin level but had no effect on kidney weight, cyst indices, kidney function, or mTOR and autophagy proteins. In summary, a standard dose of MET was ineffective in reducing PKD, did not activate p‐AMPK or suppress mTOR and the higher dose resulted in increased lactate levels and nephrotoxicity. In conclusion, the study dampens enthusiasm for human studies of MET in PKD. Doubling the metformin dose resulted in a 10‐fold increase in mean blood levels and toxicity suggesting that the dosage range between therapeutic and toxic is narrow.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycystic Kidney DiseasesCystsMetforminRenal InsufficiencyHumansAnimalsMaleRatsAMP-Activated Protein KinasesLactates

Substanzen

AMP-Activated Protein KinasesMetforminLactates

Autor:innen und Institutionen

  • Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.

ORCID-Profile: Charles L Edelstein

Förderung

  • NIDDK NIH HHS
  • BLRD VA
  • Office of Extramural Research, National Institutes of Health
  • U.S. Department of Veterans Affairs
  • Zell Family Foundation

Zitieren

APA

Oto, O. A., Atwood, D. J., Chaudhary, A., He, Z., Li, A. S., Wempe, M. F., & Edelstein, C. L. (2023). Metformin does not slow cyst growth in the PCK rat model of polycystic kidney disease. Physiological Reports. https://doi.org/10.14814/phy2.15776

Vancouver

Oto OA, Atwood DJ, Chaudhary A, He Z, Li AS, Wempe MF, et al. Metformin does not slow cyst growth in the PCK rat model of polycystic kidney disease. Physiological Reports. 2023. doi:10.14814/phy2.15776

BibTeX
@article{Oto2023,
  author = {Oto, Ozgur A and Atwood, Daniel J and Chaudhary, Anjana and He, Zhibin and Li, Amy S and Wempe, Michael F and Edelstein, Charles L},
  title = {Metformin does not slow cyst growth in the PCK rat model of polycystic kidney disease},
  journal = {Physiological Reports},
  year = {2023},
  doi = {10.14814/phy2.15776}
}
Kostenlos starten →